James F. Reddoch, EVP, Research & Investments at Royalty Pharma plc (RPRX), sold 115,964 shares at $42.40 ($4.9M) on 2021-07-06, disclosed to the SEC on 2021-07-08.
Open-market sale of $4.9M RPRX by EVP, Research & Investments. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $42.40 | 30,270 | $1.3M | 26.3% |
| 2 | $42.01 | 2,192 | $92K | 1.9% |
| 3 | $42.01 | 2,192 | $92K | 1.9% |
| 4 | $42.05 | 40,655 | $1.7M | 35.0% |
| 5 | $42.05 | 40,655 | $1.7M | 35.0% |
| Total | $42.14 avg | 115,964 |
| $4.9M |
| 100% |
| Filing → |
| RPRX | SELL | 2022-05-31 | $3.1M | — | Filing → |
| RPRX | SELL | 2022-05-23 | $3.0M | — | Filing → |
| RPRX | SELL | 2021-07-27 | $712K | — | Filing → |